Structured page family:Cost guide
Dulaglutide Cost Guide: Insurance, Cash Pay, and Savings
In the United States, Dulaglutide costs depend on brand, pharmacy, insurance design, and whether the patient qualifies for manufacturer savings programs.
Active Market
This page is designed for US treatment decisions and uses US-first pricing and savings sources.
Official pricing
Verify current pricing directly on official Trulicity pages before starting, because list pricing, self-pay offers, and eligibility terms can change.
Cash-pay reality
Official cash-pay pricing varies by pharmacy and dose. Contact multiple pharmacies or use a prescription discount service for current rates.
Insurance coverage
Commercial coverage for Dulaglutide varies by plan and indication. Prior authorization is commonly required.
Savings and coupons
Manufacturer savings programs may reduce out-of-pocket cost for eligible commercially insured patients.
Prior Authorization
Prior authorization is common and may require documentation of diagnosis, prior treatments, and clinical need.
Price Breakdown
List price (monthly)
~$900-$1,100/month (1.5 mg); higher doses proportionally more
Average wholesale price
~$800-$1,000/month
Pharmacy acquisition estimate
~$750-$900/month
Typical negotiated rate
~$550-$750/month
Price per dose
~$225 per 1.5 mg; ~$275 per 3.0 mg; ~$350 per 4.5 mg
Annual cost at list price
~$10,800-$13,200
Pharmacy Price Comparison
| Pharmacy | Price Range | Notes |
|---|---|---|
| Retail | $850-$1,100/month | Standard |
| GoodRx | $750-$950/month | Discounted |
| Lilly direct | $25/month | With savings card |
Insurance Coverage Landscape
Commercial plans
~85-95% for T2D
Medicare Part D
Covered
Medicaid
Most states cover
VA coverage
On formulary
TRICARE
Covered
Employer plan typical tier
Tier 2-3; copay $25-75
Prior Authorization Guide
Required Documentation
- •T2D diagnosis
- •Metformin trial
Common Denial Reasons
- •No metformin failure documented
- •Not T2D
Appeal Template Points
- •CV benefit (REWIND trial)
- •T2D with inadequate control
Expected timeline: 3-5 days
Savings Programs and Patient Assistance
Trulicity Savings Card
copayEligibility: Commercially insured
Savings: $25/month for 12 months
Income limit: None
Enrollment: simple
Lilly program
Lilly PAP
manufacturerEligibility: Uninsured, ≤400% FPL
Savings: Free
Income limit: ≤400% FPL
Enrollment: moderate
Annual application
Generic and Biosimilar Status
No generic currently available
Expected: No generic expected before patent expiry in 2030s
Cost by Dose
| Dose/Regimen | Monthly | Annual |
|---|---|---|
| 0.75 mg | $900 | $10,800 |
| 1.5 mg | $900 | $10,800 |
| 3.0 mg | $1,000 | $12,000 |
| 4.5 mg | $1,100 | $13,200 |
Annual Cost Projection
Year 1
$3,000-$13,200
Year 2
$3,000-$13,200
Year 3
$3,000-$13,200
Assumptions
- •T2D indication
- •Insurance stable
Cost-Saving Strategies
- 1.Trulicity savings card is highly effective ($25/month)
- 2.Higher doses (3.0, 4.5 mg) may offer better glycemic control at modest cost increase
- 3.Usually covered with simple prior auth after metformin
International Price Comparison
| Country | Price Range | Notes |
|---|---|---|
| UK | ~£120-160/month (~$150-200) | NHS |
| Canada | ~CAD $250-350 (~$190-260) | Regulated |
Need help comparing dulaglutide paths?
Use the provider matcher to package treatment interest, insurance, budget, urgency, and state context before you commit to a prescribing path.
Find a dulaglutide providerNext Step
Use the cost calculator
Use provider matching when you need help comparing insured and self-pay treatment paths.
Open tool →Retention Path
Join the Dulaglutide tracker waitlist
Capture refill timing, weekly dose history, and symptom notes in one planned workflow.
View tracker landing →Trust Summary
Reviewed 2026-04-27 by PeptideScholar editorial review. This page currently cites 2 official sources.
Pricing, savings eligibility, and coverage rules can change quickly. Verify all current figures and terms directly on official brand pages before acting.
Dulaglutide Cost FAQ
Sources
- 1. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.Lancet • 2014Claim type: clinicalView source →
- 2. FDA Information on DulaglutideFDA • 2026Claim type: regulatoryView source →
This content is for informational purposes only and does not constitute medical advice.